171 related articles for article (PubMed ID: 37579145)
1. Triple-negative breast tumors are dependent on mutant p53 for growth and survival.
Dibra D; Moyer SM; El-Naggar AK; Qi Y; Su X; Lozano G
Proc Natl Acad Sci U S A; 2023 Aug; 120(34):e2308807120. PubMed ID: 37579145
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo.
Dibra D; Xiong S; Moyer SM; El-Naggar AK; Qi Y; Su X; Kong EK; Korkut A; Lozano G
Sci Adv; 2024 Feb; 10(7):eadk1835. PubMed ID: 38354236
[TBL] [Abstract][Full Text] [Related]
3. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
4. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
5. p53R245W Mutation Fuels Cancer Initiation and Metastases in NASH-driven Liver Tumorigenesis.
Dibra D; Gagea M; Qi Y; Chau GP; Su X; Lozano G
Cancer Res Commun; 2023 Dec; 3(12):2640-2652. PubMed ID: 38047594
[TBL] [Abstract][Full Text] [Related]
6. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
7. Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases.
Zhang Y; Xiong S; Liu B; Pant V; Celii F; Chau G; Elizondo-Fraire AC; Yang P; You MJ; El-Naggar AK; Navin NE; Lozano G
Nat Commun; 2018 Sep; 9(1):3953. PubMed ID: 30262850
[TBL] [Abstract][Full Text] [Related]
8. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
9. p53 deficiency linked to B cell translocation gene 2 (BTG2) loss enhances metastatic potential by promoting tumor growth in primary and metastatic sites in patient-derived xenograft (PDX) models of triple-negative breast cancer.
Powell E; Shao J; Yuan Y; Chen HC; Cai S; Echeverria GV; Mistry N; Decker KF; Schlosberg C; Do KA; Edwards JR; Liang H; Piwnica-Worms D; Piwnica-Worms H
Breast Cancer Res; 2016 Jan; 18(1):13. PubMed ID: 26818199
[TBL] [Abstract][Full Text] [Related]
10. Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants.
Chachad D; Patel LR; Recio CV; Pourebrahim R; Whitley EM; Wang W; Su X; Xu A; Lee DF; Lozano G
Cancer Res; 2023 Jul; 83(14):2297-2311. PubMed ID: 37205631
[TBL] [Abstract][Full Text] [Related]
11. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
12. COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells.
Synnott NC; O'Connell D; Crown J; Duffy MJ
Breast Cancer Res Treat; 2020 Jan; 179(1):47-56. PubMed ID: 31538264
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
14. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K.
Liu JC; Voisin V; Wang S; Wang DY; Jones RA; Datti A; Uehling D; Al-awar R; Egan SE; Bader GD; Tsao M; Mak TW; Zacksenhaus E
EMBO Mol Med; 2014 Dec; 6(12):1542-60. PubMed ID: 25330770
[TBL] [Abstract][Full Text] [Related]
15. ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.
Bado I; Nikolos F; Rajapaksa G; Gustafsson JÅ; Thomas C
Oncotarget; 2016 Mar; 7(12):13599-611. PubMed ID: 26871946
[TBL] [Abstract][Full Text] [Related]
16. Trp53 null and R270H mutant alleles have comparable effects in regulating invasion, metastasis, and gene expression in mouse colon tumorigenesis.
Tang J; Feng Y; Kuick R; Green M; Green M; Sakamoto N; Kurosu Y; Lin J; Cho KR; Fearon ER
Lab Invest; 2019 Oct; 99(10):1454-1469. PubMed ID: 31148594
[TBL] [Abstract][Full Text] [Related]
17. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.
Yang Z; Sun JK; Lee MM; Chan MK
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36104100
[TBL] [Abstract][Full Text] [Related]
18. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
19. Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells.
Krishnan SR; Nair BC; Sareddy GR; Roy SS; Natarajan M; Suzuki T; Peng Y; Raj G; Vadlamudi RK
Breast Cancer Res Treat; 2015 Apr; 150(3):487-99. PubMed ID: 25788226
[TBL] [Abstract][Full Text] [Related]
20. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer.
Jabbour-Leung NA; Chen X; Bui T; Jiang Y; Yang D; Vijayaraghavan S; McArthur MJ; Hunt KK; Keyomarsi K
Mol Cancer Ther; 2016 Apr; 15(4):593-607. PubMed ID: 26826118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]